The impact of a fourteen-gene molecular assay on physician treatment decisions in non-small-cell lung cancer
| LEADER | caa a22 4500 | ||
|---|---|---|---|
| 001 | 605490325 | ||
| 003 | CHVBK | ||
| 005 | 20210128100504.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 210128e20150201xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1007/s10147-014-0700-8 |2 doi |
| 035 | |a (NATIONALLICENCE)springer-10.1007/s10147-014-0700-8 | ||
| 245 | 0 | 4 | |a The impact of a fourteen-gene molecular assay on physician treatment decisions in non-small-cell lung cancer |h [Elektronische Daten] |c [Shane Dormady, Michael Broder, Girish Putcha, Robert Dumanois, Alison DeCristofaro, Eunice Chang, Paul Billings, Thierry Jahan] |
| 520 | 3 | |a Background: Five-year survival in early-stage, non-squamous, non-small-cell lung cancer (NSCLC) remains poor compared with other solid tumors, even after complete resection. Post-operative management depends on prognostic staging to identify individuals at highest risk for death, and therefore with the greatest need for further intervention. A 14-gene quantitative RT-PCR test successfully differentiates stage I-III NSCLC patients who are at high-, intermediate-, or low-risk for 5-year mortality. This study assesses the impact of the assay's prognostic information on physician decisions regarding adjuvant chemotherapy. Methods: We invited 115 physicians who ordered the test to participate in an on-line survey. The primary outcome measure was the proportion of patients with different pre- and post-test chemotherapy recommendations. Results: Fifty-eight physicians (50%) completed the survey on 120 stage I or II NSCLC patients. Ninety-one patients (76%) had stage I lung cancer; 27 (23%), 39 (33%), and 54 (45%) patients had low-, intermediate-, and high-risk scores, respectively. Physicians' chemotherapy recommendations were changed post-testing in 37 patients (30.8%, 95% CI 22.7-39.9%). High-risk patients were more likely to have a change in treatment recommendation (44.4%, 95% CI 30.9-58.6%) than low risk patients (3.7%, 95% CI 0.1-19.0%); a substantial number of changes were observed in both stage I (33.0%, 95% CI 23.5-43.6%) and stage II (24.1%, 95% CI 10.3-43.5%). Conclusions: Our data show that the assay resulted in a significant impact on physician treatment decisions in early-stage NSCLC, and that the nature of treatment changes generally correlated with the test's assessment of risk. | |
| 540 | |a Japan Society of Clinical Oncology, 2014 | ||
| 690 | 7 | |a Lung cancer |2 nationallicence | |
| 690 | 7 | |a Chemotherapy |2 nationallicence | |
| 690 | 7 | |a Medical decision-making |2 nationallicence | |
| 700 | 1 | |a Dormady |D Shane |u Valley Medical Oncology Consultants, 2940 Whipple Ave., Redwood City, CA, USA |4 aut | |
| 700 | 1 | |a Broder |D Michael |u Partnership for Health Analytic Research, LLC, 280 South Beverly Drive, Suite 404, 90212, Beverly Hills, CA, USA |4 aut | |
| 700 | 1 | |a Putcha |D Girish |u Life Technologies Corporation, 5791 Van Allen Way, 92008, Carlsbad, CA, USA |4 aut | |
| 700 | 1 | |a Dumanois |D Robert |u Life Technologies Corporation, 5791 Van Allen Way, 92008, Carlsbad, CA, USA |4 aut | |
| 700 | 1 | |a DeCristofaro |D Alison |u Partnership for Health Analytic Research, LLC, 280 South Beverly Drive, Suite 404, 90212, Beverly Hills, CA, USA |4 aut | |
| 700 | 1 | |a Chang |D Eunice |u Partnership for Health Analytic Research, LLC, 280 South Beverly Drive, Suite 404, 90212, Beverly Hills, CA, USA |4 aut | |
| 700 | 1 | |a Billings |D Paul |u Life Technologies Corporation, 5791 Van Allen Way, 92008, Carlsbad, CA, USA |4 aut | |
| 700 | 1 | |a Jahan |D Thierry |u Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, Box 1724, 94143-1724, San Francisco, CA, USA |4 aut | |
| 773 | 0 | |t International Journal of Clinical Oncology |d Springer Japan |g 20/1(2015-02-01), 59-69 |x 1341-9625 |q 20:1<59 |1 2015 |2 20 |o 10147 | |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s10147-014-0700-8 |q text/html |z Onlinezugriff via DOI |
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 900 | 7 | |a Metadata rights reserved |b Springer special CC-BY-NC licence |2 nationallicence | |
| 908 | |D 1 |a research-article |2 jats | ||
| 949 | |B NATIONALLICENCE |F NATIONALLICENCE |b NL-springer | ||
| 950 | |B NATIONALLICENCE |P 856 |E 40 |u https://doi.org/10.1007/s10147-014-0700-8 |q text/html |z Onlinezugriff via DOI | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Dormady |D Shane |u Valley Medical Oncology Consultants, 2940 Whipple Ave., Redwood City, CA, USA |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Broder |D Michael |u Partnership for Health Analytic Research, LLC, 280 South Beverly Drive, Suite 404, 90212, Beverly Hills, CA, USA |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Putcha |D Girish |u Life Technologies Corporation, 5791 Van Allen Way, 92008, Carlsbad, CA, USA |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Dumanois |D Robert |u Life Technologies Corporation, 5791 Van Allen Way, 92008, Carlsbad, CA, USA |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a DeCristofaro |D Alison |u Partnership for Health Analytic Research, LLC, 280 South Beverly Drive, Suite 404, 90212, Beverly Hills, CA, USA |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Chang |D Eunice |u Partnership for Health Analytic Research, LLC, 280 South Beverly Drive, Suite 404, 90212, Beverly Hills, CA, USA |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Billings |D Paul |u Life Technologies Corporation, 5791 Van Allen Way, 92008, Carlsbad, CA, USA |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Jahan |D Thierry |u Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, Box 1724, 94143-1724, San Francisco, CA, USA |4 aut | ||
| 950 | |B NATIONALLICENCE |P 773 |E 0- |t International Journal of Clinical Oncology |d Springer Japan |g 20/1(2015-02-01), 59-69 |x 1341-9625 |q 20:1<59 |1 2015 |2 20 |o 10147 | ||